Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JDHD | ISIN: IL0011417206 | Ticker-Symbol: 4SG
Frankfurt
01.11.24
08:01 Uhr
0,402 Euro
-0,048
-10,67 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SOL-GEL TECHNOLOGIES LTD Chart 1 Jahr
5-Tage-Chart
SOL-GEL TECHNOLOGIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,4600,49813:05

Aktuelle News zur SOL-GEL TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.09.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer3
27.08.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
16.08.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
16.08.Sol-Gel Technologies Ltd.: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates169Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with...
► Artikel lesen
25.07.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
15.07.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
15.07.Sol-Gel Technologies CEO To Step Down; Eyal Ben-Or Appointed As CFO-
15.07.Sol-Gel Technologies announces CEO Seri-Levy to step down; promotes Eyal Ben-Or as CFO2
15.07.Sol-Gel Technologies Ltd.: Sol-Gel Technologies Announces Management Realignment2
28.05.Sol-Gel Technologies gets non-compliance notice from Nasdaq1
28.05.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
20.05.Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates171Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China...
► Artikel lesen
17.05.Sol-Gel, Beimei sign deal for TWYNEO commercialisation1
16.05.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
16.05.Sol-Gel Technologies Ltd.: Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO in the Mainland of China, Hong Kong, Macau, Taiwan and Israel136NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a...
► Artikel lesen
01.04.Sol-Gel Technologies Ltd.: Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream596NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a...
► Artikel lesen
13.03.Sol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments 420An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025...
► Artikel lesen
30.11.23Sol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study520SGT-610 has "Orphan Drug" designation status in the U.S. and E.U. and "Breakthrough Therapy" designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs...
► Artikel lesen
09.11.23Sol-Gel Technologies Ltd.: Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update192Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1